EML4-ALK: honing in on a new target in non-small-cell lung cancer.
暂无分享,去创建一个
[1] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Ratain,et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Hwang,et al. Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Y. Ishikawa,et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.
[5] A. Sihoe,et al. The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.
[6] Y. Ishikawa,et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.
[7] E. Campo,et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. , 2009, The American journal of pathology.
[8] Y. Ishikawa,et al. A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.
[9] Gudrun Schleiermacher,et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.
[10] S. Ogawa,et al. Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.
[11] Y. Ishikawa,et al. Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.
[12] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[13] D. Gary Gilliland,et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.
[14] H. Sugimura,et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. , 2008, Lung cancer.
[15] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Yuki Togashi,et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.
[17] Derek Y. Chiang,et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.
[18] M. Ladanyi,et al. Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.
[19] A. Iafrate,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.
[20] T. Utsunomiya,et al. EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers , 2008, British Journal of Cancer.
[21] Francesca Demichelis,et al. EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.
[22] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[23] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[25] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[26] C. Fletcher,et al. Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases , 2007, The American journal of surgical pathology.
[27] Peter G. Schultz,et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.
[28] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[29] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[31] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[33] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[34] M. Valentine,et al. Sequence Correction , 1995, Science.
[35] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.